Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors

Hepatology

Volumn 31, Issue 3, 2000, Pages 587-591

  Denninger, Marie Hélène ^a   Chaït, Yasmine ^a   Casadevall, Nicole ^a   Hillaire, Sophie ^b   Guillin, Marie Claude ^a   Bezeaud, Annie ^a   Erlinger, Serge ^b   Briere, Jean ^a   Valla, Dominique ^a,b  

^a BEAUJON HOSPITAL   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; HUMAN; LIVER VEIN THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR;

EID: 0033999779     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310307     Document Type: Article

References (23)

1. Shafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994;344:1739-1742.
2. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, Binda B, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988;94:1063-1069.
3. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Malliard J-N, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:329-334.
4. Pelletier S, Landi B, Piette JC, Ekert P, Coutelier A, Fadlallah JP, Herson S, et al. Antiphospholipid syndrome as the second cause of nontumorous Budd-Chiari syndrome. J Hepatol 1994;21:76-80.
5. Denninger MH, Helley D, Valla D, Guillin MC. Prospective evaluation of the prevalence of factor V Leiden mutation in portal or hepatic vein thrombosis. Thromb Haemost 1997;78:1297-1298.
6. Van Gansbeke D, Avni EF, Delcour C, Engelholm L, Struyven J. Sonographic features of portal vein thrombosis. AJR Am J Roentgenol 1985;144:749-752.
7. Valla D, Benhamou JP. Obstruction of the hepatic veins or suprahepatic inferior vena cava. Dig Dis 1996;14:99-118.
8. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Van der Velpen PA, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369: 64-67.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
10. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10: 111-113.
11. Berlin NI: Classification of the polycythemias and initial clinical features in polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: WB Saunders, 1995;22-30.
12. Iland H, Laszlo J, Murphy S: Essential thrombocythemia. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: WB Saunders, 1995;293-310.
13. Reid CD, Chanarin I, Lewis J. Formes frustes in myeloproliferative disorders. Identification by the growth of an endogenous erythroid clone in vitro in patients with arterial vascular disease. Lancet 1982;1:14-16.
14. Schubert J, Alvarado M, Uciechowski P, Zielinska-Skowronek M, Freud M, Vogt H, Schmidt RE. Diagnosis of paroxysmal nocturnal haemoglobin-uria using immunophenotyping of peripheral blood cells. Br J Haematol 1991;79:487-492.
15. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemos 1987;57:144-147.
16. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997;23:411-418.
17. Zöller B, Hilm J, Dahlback B. Resistance to activated protein C due to a factor V gene mutation. The most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996;6:45-53.
18. Mahmoud AEA, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997;40:798-800.
19. Chamouard P, Pencrach E, Maloisel E. Grunebaum L, Ardizzone JF, Meyer A, Gaub M-P, et al. Frequent factor II G20210 mutation in idiopathic portal vein thrombosis. Gastroenterology 1999;116:144-148.
20. Maraglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaconne L, Vecchione G, et al. Increased risk for venous thrombosis in carriers of the prothombin G-A 20210 gene variant. Ann Intern Med 1998;129:89-93.
21. Den Heijer M, Rosendaal, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-877.
22. Wicken DEL. MTHFR 677C-T mutation, folate intake, neural tube defect, and risk of cardiovascular disease. Lancet 1997;350:603-604.
23. Robson SC, Kahn D, Kruskal J, Bird AR, Kirsch RE. Disordered hemostasis in extrahepatic portal hypertension. HEPATOLOGY 1993;18:853-857.